Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Short term Debt (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Short term Debt for 3 consecutive years, with $7.3 million as the latest value for Q4 2025.

  • Quarterly Short term Debt rose 373.72% to $7.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.3 million through Dec 2025, up 373.72% year-over-year, with the annual reading at $7.3 million for FY2025, 373.72% up from the prior year.
  • Short term Debt for Q4 2025 was $7.3 million at Rhythm Pharmaceuticals, up from $5.6 million in the prior quarter.
  • The five-year high for Short term Debt was $7.3 million in Q4 2025, with the low at $1.5 million in Q4 2024.